Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

721. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease

The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease Hussey G D, Lasser M L, Reekie W D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination for Haemophilus influenzae type B (HiB) disease. Type of intervention Primary prevention Economic study type Cost-benefit analysis Study population Cohort of children born in 1992 Setting Primary care. The economic study was carried out in Cape Town Province, Republic of South Africa. Dates to which data relate 1992 births to age 100 simulation. 1992 prices were

1995 NHS Economic Evaluation Database.

722. Immunogenicity of new virosome influenza vaccine in elderly people. (Abstract)

Immunogenicity of new virosome influenza vaccine in elderly people. The safety and immunogenicity of a new virosome influenza vaccine was compared to commercial whole-virus vaccine and subunit vaccine in elderly people. The virosome vaccine was made by extracting the haemagglutinin from influenza virus and incorporating it into the membrane of liposomes composed of phosphatidylcholine (PC) and phosphatidylethanolamine (PE). 126 residents of a nursing home, aged 63-102, were randomised

1994 Lancet Controlled trial quality: uncertain

723. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. (Abstract)

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. To determine the efficacy of influenza vaccination in elderly people.Randomized double-blind placebo-controlled trial.Fifteen family practices in the Netherlands during influenza season 1991-1992.A total of 1838 subjects aged 60 years or older, not known as belonging to those high-risk groups in which vaccination was previously given.Purified split-virion vaccine containing (...) A/Singapore/6/86(H1N1), A/Beijing/353/89(H3N2), B/Beijing/1/87, and B/Panama/45/90 (n = 927) or intramuscular placebo containing physiological saline solution (n = 911).Patients presenting with influenzalike illness up to 5 months after vaccination; self-reported influenza in postal questionnaires 10 weeks and 5 months after vaccination; serological influenza (fourfold increase of antibody titer between 3 weeks and 5 months after vaccination).The incidence of serological influenza was 4% in the vaccine

1994 JAMA Controlled trial quality: predicted high

724. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. (Abstract)

Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. To assess the effect of priming with diphtheria and tetanus toxoid vaccine (DT) at 1 month of age on the anticapsular polyribosylribitol phosphate (PRP) antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate (PRP-T) or PRP oligosaccharide-cross-reactive mutant diphtheria toxin conjugate (HbOC).Randomized controlled

1994 JAMA Controlled trial quality: uncertain

725. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies

Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus (...) influenzae: a meta-analysis of 12 clinical studies Cooper B C, Mullins P R, Jones M R, Lang S D Authors' objectives To: (1) establish the clinical and bacteriological efficacy of roxithromycin against adult respiratory tract infections caused by Haemophilus influenzae on a per protocol and intention to treat basis; (2) compare the clinical efficacy of once and twice daily regimens of roxithromycin; (3) compare the efficacy of roxithromycin with standard antibiotics; (4) assess the correlation between

1994 DARE.

726. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP

The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) favourably with other medical interventions. CRD Commentary The cost analysis could be clearer. Moreover, no satisfactory explanation was provided for the calculation of QALYs. Source of funding Merck Sharp and Dohme(Australia) Pty Ltd. Bibliographic details Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Medical Journal of Australia 1994; 160: 483-488 PubMedID Indexing Status

1994 NHS Economic Evaluation Database.

727. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Mullooly J P, Bennett M D, Hornbrook M C, Barker W H, Williams W W, Patriarca P A, Rhodes P H Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination against influenza. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Elderly males and females (aged 65+). High risk participants werethose who had medical care contacts for chronic pulmonary

1994 NHS Economic Evaluation Database.

728. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community Full Text available with Trip Pro

The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community Nichol K L, Margolis K L, Wuorenma R N, Von Sternberg T Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination against influenza Type of intervention Primary prevention Economic study type Cost-effectiveness analysis Study population All persons aged 65 or over, enrolled in a Health Maintenance Organisation (HMO). Setting The practice setting was primary care. The economic study

1994 NHS Economic Evaluation Database.

729. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB)

Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Trollfors B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccine against Haemophilus influenzae type b (HIB) Type of intervention Primary prevention Economic study type Cost-benefit analysis Study population Children aged 0-14 years. Setting Primary care. The economic study was carried out in Sweden. Dates to which data relate Information on effectiveness related to 1981-83. Dates for resource data were not clearly specified. Price data was not given

1994 NHS Economic Evaluation Database.

730. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. Full Text available with Trip Pro

Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. To assess the frequency and type of side effects after influenza vaccination in elderly people.Randomised double blind placebo controlled study.15 general practices in the southern Netherlands.1806 patients aged 60 or older, of whom 904 received influenza vaccine and 902 placebo.Adverse reactions reported on postal questionnaire completed four weeks after vaccination.210 (23%) patients

1993 BMJ Controlled trial quality: predicted high

731. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. (Abstract)

Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. To assess whether serum antibody responses to diphtheria-tetanus-pertussis (DTP) vaccine were affected by coadministration of Haemophilus influenzae type b capsular polyribosylribitol phosphate polysaccharide-tetanus protein (PRP-T) conjugate vaccine when given to patients at 2, 4, and 6 months of age.Randomized, double-blind

1992 JAMA Controlled trial quality: uncertain

732. Achieving compliance with influenza immunization of medical house staff and students. A randomized controlled trial. (Abstract)

Achieving compliance with influenza immunization of medical house staff and students. A randomized controlled trial. To determine the optimal method to increase influenza immunization rates of medical house staff and students.Prospective randomized trial and cross-sectional survey.Four hundred forty-two internal medicine, obstetrics-gynecology, and general surgery residents and junior medical students.The four interventions employed were (1) an educational memorandum outlining vaccine (...) that only 32% had ever been previously immunized against influenza, yet 70% stated that they had worked despite having influenzalike symptoms.A high rate of immunization of house staff and medical students can be achieved most effectively by offering vaccine in clinics and conferences. Continued education about influenza immunization is necessary for physicians and medical students.

1992 JAMA Controlled trial quality: uncertain

733. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. (Abstract)

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. Several conjugate vaccines against Haemophilus influenzae type b have been developed in the search for one that induces protection even in young infants. We evaluated the safety and efficacy of a conjugate vaccine that links the H. influenzae type b capsular polysaccharide to the outer-membrane protein complex (OMPC (...) ) of Neisseria meningitidis serogroup B. We conducted a double-blind, placebo, controlled trial in Navajo infants, who are at high risk for systemic infections caused by H. influenzae type b. The infants were randomly assigned to receive the first dose of vaccine or placebo at 42 to 90 days of age and the second at 70 to 146 days of age.Of the infants in the trial, 2588 were assigned to receive the vaccine and 2602 to receive placebo. The mean follow-up was 269 days in the vaccine group and 267 days

1991 NEJM Controlled trial quality: predicted high

734. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. (Abstract)

Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. Persons with human immunodeficiency virus (HIV) infection are at increased risk for serious infections caused by Haemophilus influenzae, yet there are few data on their antibody responses to the H. influenzae type b vaccines.We evaluated antibody responses in 248 men who were randomly assigned to receive a single dose of either the H. influenzae type b polysaccharide (PRP) vaccine (...) or the polysaccharide-mutant diphtheria toxoid conjugate vaccine (PRP-CRM). The subjects were stratified into four groups: seronegative men (67 subjects), men with asymptomatic HIV infection (79), men with symptomatic HIV infection (47), and men with the acquired immunodeficiency syndrome (AIDS) (55).Before immunization, the subjects with AIDS had the lowest PRP-antibody titers; 40 percent had titers below the putative protective level (less than 0.15 micrograms per milliliter). In the seronegative subjects, those

1991 NEJM Controlled trial quality: uncertain

735. Haemophilus influenzae diphtheria protein conjugate immunization after therapy in splenectomized patients with Hodgkin disease. (Abstract)

Haemophilus influenzae diphtheria protein conjugate immunization after therapy in splenectomized patients with Hodgkin disease. 2294819 1990 02 06 2004 11 17 0003-4819 112 2 1990 Jan 15 Annals of internal medicine Ann. Intern. Med. Haemophilus influenzae diphtheria protein conjugate immunization after therapy in splenectomized patients with Hodgkin disease. 143-4 Jakacki R R Children's Hospital, Philadelphia, Pennsylvania. Luery N N McVerry P P Lange B B eng Clinical Trial Journal Article (...) Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Antibodies, Bacterial 0 Bacterial Vaccines 0 Diphtheria Toxoid 0 Haemophilus Vaccines 0 Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate AIM IM Adolescent Adult Antibodies, Bacterial biosynthesis Bacterial Vaccines adverse effects immunology Child Diphtheria Toxoid adverse effects immunology Female Haemophilus Infections prevention & control Haemophilus Vaccines Haemophilus influenzae immunology

1990 Annals of Internal Medicine Controlled trial quality: uncertain

736. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. (Abstract)

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. Haemophilus influenzae type b is the leading cause of invasive bacterial disease in young children. The capsular polysaccharide vaccine does not protect children at greatest risk (those under the age of 18 months), but a polysaccharide-protein conjugate vaccine has proved to be more immunogenic in this age group.We enrolled 114,000 (...) infants in Finland in an open, prospective, randomized trial of a H. influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (polyribosylribitol phosphate-diphtheria toxoid [PRP-D]). Children born on odd-numbered days were vaccinated at the ages of 3, 4, 6, and 14 to 18 months; those born on even-numbered days formed the control group and received the same vaccine at the age of 24 months.After three doses of the vaccine there were 4 cases of verified bacteremic H. influenzae type

1990 NEJM Controlled trial quality: uncertain

737. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. (Abstract)

Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. The prevention of invasive Haemophilus influenzae type b disease requires a vaccine that is effective when administered during the first six months of life. The infants of Alaska Natives are at particularly high risk of invasive H. influenzae type b disease.To evaluate the protective efficacy of a H. influenzae type b polysaccharide-diphtheria toxoid (...) conjugate vaccine (polyribosylribitol phosphate-diphtheria toxoid [PRP-D]), we enrolled 2102 Alaska Native infants in a randomized, double-blind, placebo-controlled trial in which either the vaccine or a saline placebo was administered at approximately two, four, and six months of age.After 3969 subject-years of follow-up and 32 episodes of H. influenzae type b disease, the overall incidence of invasive disease was not reduced significantly in the vaccinated subjects (6.0 cases per 1000 patient-years

1990 NEJM Controlled trial quality: predicted high

738. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. (Abstract)

Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. Concern about side effects constitutes a major deterrent to patient compliance with influenza vaccination, yet there is a paucity of data about the occurrence of adverse reactions in the population targeted for immunization. We conducted a randomized, double-blind, crossover trial to compare the frequency of adverse reactions following administration of 1988-1989 trivalent split-antigen (...) influenza vaccine and saline placebo. Outpatient veterans 65 years of age or over (n = 336) were recruited by mail and were randomly assigned to receive vaccine followed 2 weeks later by placebo injection or placebo followed 2 weeks later by vaccine. There was no significant difference between influenza vaccine and placebo with respect ot the proportion of subjects reporting disability or systemic symptoms.

1990 JAMA Controlled trial quality: predicted high

739. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. (Abstract)

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. To determine whether rimantadine can protect family members from acquiring influenza A viral illness and to assess the possible selection of drug-resistant strains of virus, we conducted a randomized, double-blind, placebo-controlled study in three communities during two influenza seasons. When influenza A occurred in a family, the members (including the index patient) were given either rimantadine (...) (adult oral dose, 200 mg per day) or placebo for 10 days. The presence of illness was monitored by daily recording of symptoms and temperature measurements; infection was determined by isolation of the virus and by serologic studies. Among households with documented influenza A infections, symptomatic illness occurred in one or more contacts in 10 of 28 families treated with rimantadine and in 10 of 209 families treated with placebo. Asymptomatic secondary influenza A infections were found in five

1989 NEJM Controlled trial quality: uncertain

740. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. (Abstract)

Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. Apache Indian infants have a high frequency of Haemophilus influenzae type b (Hib) and pneumococcal infections. Forty percent of Hib infections in these infants occur before the age of six months, when active immunization may not be protective. To evaluate the efficacy of passive immunization with a human hyperimmune globulin (bacterial polysaccharide immune

1987 NEJM Controlled trial quality: uncertain